Thu, Jul 24, 2014, 4:56 AM EDT - U.S. Markets open in 4 hrs 34 mins

Recent

% | $
Click the to save as a favorite.

Aegerion Pharmaceuticals, Inc. (AEGR) Message Board

betonthenews 63 posts  |  Last Activity: Jul 3, 2014 12:38 PM Member since: Nov 27, 2007
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • betonthenews by betonthenews Jul 3, 2014 12:38 PM Flag

    We know:
    registration deadline
    The registration deadline is July 7, 2014. After this date, you must contact
    Brenda Ram, CMP, CCMEP at 402-559-9250 to check conference space
    availability. Please note, conference materials cannot be guaranteed
    unless pre-registered by July 7, 2014.

    Conference materials
    The conference materials will be available via an online app for all paid
    conference attendees.

    I guess any date after July 7, abstract may be available to attendees,
    so market may know too, I guess.

  • Reply to

    Welcome to July

    by jet_powered_chicken Jul 3, 2014 9:50 AM
    betonthenews betonthenews Jul 3, 2014 12:13 PM Flag

    I agree with you, but the final may still succeed but critics may argue how useful the
    treatments are, how to identify the patients who can benefit, DNDN's Provenge's story
    come to mind.

  • betonthenews betonthenews Jul 2, 2014 12:54 PM Flag

    Market estimates Ibrutinib peak sales about $4B, if 1101 + 1202 combo is approved
    by FDA, the combo may take at least $1.5B peak sales away from Ibrutinib.

  • betonthenews betonthenews Jul 2, 2014 12:39 PM Flag

    Look at PCYC stock history, PCYC traded from $12 in DEC 2012,
    and $70 in July 2013 after PII results. TGTX PII results come in
    DEC 2014.

  • betonthenews betonthenews Jul 2, 2014 12:35 PM Flag

    Ibrutinib(+100+K/year) correction: Ibrutinib costs $100+K/year
    How much is TGTX CEO Michael S. Weiss is willing to sell?
    I would guess at least $1.75 to $2B before year end, or much
    more if TGTX is in PIII trials next year.

  • betonthenews betonthenews Jul 2, 2014 12:29 PM Flag

    If the coming up initial '1101 + '1202 combination data is as good as
    the 1101+Ibrutinib(90% ORR), TGTX can price the '1101 + '1202 combination
    in line with Ibrutinib(+100+K/year) and get most patients from PCYC, then
    PCYC has no choice but to buy out TGTX before year end.

  • Reply to

    BMY's early PIII trial stop.....

    by betonthenews Jun 25, 2014 1:58 PM
    betonthenews betonthenews Jun 27, 2014 9:30 AM Flag

    Here is the reason why NLNK has the first look:

    Charles Link
    You know Steve, when we look back at the phase II data, I think that what were struck by and we didn’t really fully understand, you know the phase II data didn’t have treatment arms. So the phase II data was limited. But one think that we know was true is that in the high dose group that one year out of the 26 stations, only a single patient had died and that really exceeded any expectations that experts in the field had for what would happen in terms of one year survival and that one patient when we looked at that patient had a 12 centimeter tumor, a fairly enormous tumor [indiscernible] surgery perspective.

    So we felt that that single fact the survival of one year was a very strong efficacy signal for the trial in the high dose group and we did believe that we’ve evidence of those responsiveness in both lung cancer and pancreatic cancer that then let us to do this 12 months treatment plan. And so, since we didn’t loss much alpha, we thought why not take an early look at this if there was more dose responsiveness and more duration responsiveness in the clinical effect maybe there could be something of that magnitude. So, that’s what we did.

  • Reply to

    BMY's early PIII trial stop.....

    by betonthenews Jun 25, 2014 1:58 PM
    betonthenews betonthenews Jun 26, 2014 7:09 PM Flag

    If you use 80%(guessing here) 12 month survival rate for control arm, you may see
    different results, I speculate the control arm is performing much better then the
    SOC history indicates at first 12 month of the trial, IMO.

  • Reply to

    BMY's early PIII trial stop.....

    by betonthenews Jun 25, 2014 1:58 PM
    betonthenews betonthenews Jun 26, 2014 12:10 PM Flag

    I am arguing HyperAcute may work on small number of patients very well,
    but no effect on majority of the patients, hence no early separation, but
    big fat tail KM curve, that is the risk we are trying to figure out.

  • Reply to

    BMY's early PIII trial stop.....

    by betonthenews Jun 25, 2014 1:58 PM
    betonthenews betonthenews Jun 26, 2014 12:02 PM Flag

    Understand, but the curve separation has big meaning for second look too,
    I may be wrong, here is how I see it. Next most of the 111 events may be coming
    from the patients enrolled in the less than 24 month, and if the curves are separating
    at 12 to 14 month time mark, then few 36+ month long term patients advantage in treatment
    arm may not bring the P value to stop the second look, but final has a good chance
    for success, IMO.

  • Reply to

    hard resistance at $60?

    by not_totally_gray Jun 25, 2014 12:56 PM
    betonthenews betonthenews Jun 25, 2014 6:19 PM Flag

    After hour trade, 400 shares at 60.30....

  • Reply to

    BMY's early PIII trial stop.....

    by betonthenews Jun 25, 2014 1:58 PM
    betonthenews betonthenews Jun 25, 2014 6:02 PM Flag

    I am trying to argue with Jet that HR is the number that
    determines the OS advantage, not the MOS. HR is determined
    by the curve separation, earlier = lower HR, like I said before
    if the IMPRESS trial curves separate at 6 month time mark with
    a 5 month MOS advantage, 25 VS 20, should be enough to stop
    the trial at first look. MDVN's trial was stopped early for only 2 month
    MOS advantage but with HR=0.7, a 30% reduction in risk of death
    compared with placebo, p less than 0.0001. I am not buying the NLNK's
    view that " the reason was insufficient follow up due to over half of the patients being enrolled later in the game (they haven't/couldn't have enough follow up time yet) This has nothing to do with the shape of our curve."

  • Reply to

    BMY's early PIII trial stop.....

    by betonthenews Jun 25, 2014 1:58 PM
    betonthenews betonthenews Jun 25, 2014 4:06 PM Flag

    Check out BMY's PIII CheckMate 066 which stopped today at clinicaltrials.gov,
    the trial started on NOV 2 2012, and finished the enrollments for 418 patients
    on Feb 28, 2014!

  • NEW YORK (AP) -- Bristol-Myers said Tuesday that its skin cancer drug nivolumab worked in a late-stage clinical trial, leading the drugmaker to end the study early.

    I think BMY news today supports my view IMPRESS trial KM curves are not separating
    early, otherwise first look should be a stop.

  • Reply to

    hard resistance at $60?

    by not_totally_gray Jun 25, 2014 12:56 PM
    betonthenews betonthenews Jun 25, 2014 1:36 PM Flag

    I see 60 is overcome tomorrow and 63 to 65 next Thur before the independent holidays.
    No sellers, and the 4000K July options sellers many of which naked are under pressure
    to cover.

  • Company guidance is EBITDA of a $115 million to $135 million in 2014
    and 2015 EBITDA with a range of $140 million to $185 million.

    TJ Schultz - RBC Capital Markets
    Hi everybody, good morning. I appreciate the guidance update certainly reflective of the strong market here. The range is fairly wide given, some of the take or pay contracts. So, I think Laura may be you touched on this a little bit, but if you could maybe discuss some of the factors driving you to the high and low end of these ranges whether it’s a more volume or price sensitive?

    Laura Fulton
    I would say it’s more volume sensitive and it really is dependent upon our ability to execute and bring the Augusta facilities online, the expansion of the Augusta facility online in the third quarter as we planned to do. I’m sure that happened and we probably are operating towards the higher end of that range as we are able to produce more sand to sell through the distribution business to those customers that don’t have contracts.

    We can see the expansion of the Augusta facility online in the third quarter is the only risk
    HCLP may not reach the high end of guidance which is very very low, so we may see street
    raise 2014 and 2015 earnings estimates to 135/33.13=$4.07 and 185/33.13=$5.58 after Q2
    earnings report in Aug, very likely with one more price increase in Q3 or Q4, IMO.

  • Reply to

    $50 or $70?

    by bridgejumper08 Jun 18, 2014 2:42 PM
    betonthenews betonthenews Jun 19, 2014 12:43 PM Flag

    I do not think 70 will get the deal done. Three reasons:
    1. ORCL wants and gets exclusive talks and ORCl better ready to pay
    because it is not in best interest of MCRS not to let other also trying to
    get in the deal(rumor SAP, IBM).
    2. MCRS investment banker leaked the talks to get the stock price up to
    argue for a fair buyout price, it is obvious OCRL is trying to low ball the
    offer.
    3. MCRS is buying back shares aggressively confident the shares are cheap.
    With the strong business and with annual operating Cash Flow $240M cash
    and strong cash balance, MCRS can buy back tens of million shares in few years
    and share price will go up to 75 without buyout. It is very obvious ORCL wants
    MCRS and MCRS wants a big fair premium in this kind of bull market.

  • betonthenews betonthenews Jun 18, 2014 6:58 PM Flag

    Safety and tolerability assessments based on adverse events (AEs), clinical laboratory values (hematology, serum chemistry, coagulation studies, and urinalysis), standard digital electrocardiograms (ECGs), vital signs, and pulse oximetry [ Time Frame: From Baseline and up to 28 Weeks ] [ Designated as safety issue: Yes ]

    My understanding is the trial is Double Blinded and Placebo patients will cross over to get
    the drug treatments after they finish the 28 week trial. how can VRTX compare the two arms
    of Safety and tolerability assessments if the trial finish at 24 weeks? Besides, the STRIVE trial
    only had 164 patients and took 10 weeks to scrub and clean the data base for the results,
    the two combo trials have 1100+ patients and have 6X more data to scrub and clean that takes
    lot of time to do, any way that is just my guess according to VRTX history of reporting PIII results.

  • betonthenews betonthenews Jun 18, 2014 2:19 PM Flag

    Correction, the two trials ended on May 2, 2014 and 10 weeks
    is at July 11, My guess is the combo results at the earliest are
    week of July 14, all IMO.

  • 167 patients enrollment finish: Jan 12, 2010
    48 weeks trial end: Dec 12, 2010
    10 weeks after the trial end: Feb 22, 2011
    Results news: FEB 23, 2011, exactly 10 weeks after the trial ends.
    167 patients enrollment

    The two combo TRAFFIC and TRANSPORT trial time line:
    1100+ patients enrollment finish: OCT 18, 2013
    28 weeks trial end: Apr 2, 2014
    10 weeks after the trial end: July 11, 2014
    Results out: July 1? or 2?, 2014

AEGR
28.75+1.07(+3.87%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Xilinx Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT